Role of male partner involvement in ART retention and adherence in Malawi's Option B+ program.

Published

Journal Article

Malawi's Option B+ program provides all HIV-infected pregnant women free lifelong antiretroviral therapy (ART), but challenges remain regarding retention and ART adherence, potentially due to male partner barriers. We explored relationships between male partner involvement and Option B+ retention and adherence. In 2014, a randomized controlled trial in Malawi compared male recruitment strategies for couple HIV testing and counseling (cHTC) at an antenatal clinic. This secondary analysis was conducted among the entire cohort (N = 200) of women, irrespective of randomization status. We assessed whether cHTC attendance, early disclosure of HIV-positive status, and partner ART reminders were associated with retention and adherence at one month after starting treatment. Retention was defined as attending HIV clinic follow-up within one day of running out of pills. Adherence was defined as taking ≥95% of ARTs by pill count. We used binomial regression to calculate adjusted risk ratios (aRR) and 95% confidence intervals (CI). Median female age was 26 years. Most women (79%) were retained; of these, 68% were adherent. Receiving cHTC was associated with improved retention (aRR 1.33, 95% CI 1.12, 1.59). Receiving male partner ART reminders was weakly associated with retention (aRR 1.16, 95% CI 0.96, 1.39). Disclosure within one day was not associated with retention (aRR 1.08, 95% CI: 0.91, 1.28). Among those who were retained, these three behaviors were not associated with improved 95% adherence. CHTC could play an important role in improving Option B+ retention. Increasing cHTC participation and enhancing adherence-related messages within cHTC are important.

Full Text

Duke Authors

Cited Authors

  • Wesevich, A; Mtande, T; Saidi, F; Cromwell, E; Tweya, H; Hosseinipour, MC; Hoffman, I; Miller, WC; Rosenberg, NE

Published Date

  • November 2017

Published In

Volume / Issue

  • 29 / 11

Start / End Page

  • 1417 - 1425

PubMed ID

  • 28355926

Pubmed Central ID

  • 28355926

Electronic International Standard Serial Number (EISSN)

  • 1360-0451

International Standard Serial Number (ISSN)

  • 0954-0121

Digital Object Identifier (DOI)

  • 10.1080/09540121.2017.1308464

Language

  • eng